{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:32Z","timestamp":1787026652068,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune thrombocytopenia(ITP)is a common clinical manifestation of systemic lupus erythematosus(SLE). Drug therapy includes glucocorticoids(GCs),disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Refractory thrombocytopenia can be life-threatening, and the use of effective medications plays a crucial role in disease improvement. Here, we report a case of ITP secondary to SLE. The use of dexamethasone(DEX), cyclosporine A(CsA), and hetrombopag resulted in drug-induced liver injury. Subsequently, telitacicept was chosen and successfully controlled the patient\u2019s condition. It suggests that telitacicept may be a new treatment option for refractory SLE-ITP.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1473190","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T01:16:41Z","timestamp":1742347001000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful treatment of refractory systemic lupus erythematosus-associated immune thrombocytopenia with drug-induced liver injury with telitacicept: a case report and review"],"prefix":"10.3389","volume":"16","author":[{"given":"Xuefei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiQin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102887","article-title":"Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatment","volume":"132","author":"Jiang","year":"2022","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2022.J074","article-title":"Telitacicept for recalcitrant cutaneous manifestations of systemic lupus erythematosus: A case report and review of the literature","volume":"258","author":"Ma","year":"2022","journal-title":"Tohoku J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268929","article-title":"Case report: Successful treatment of refractory membranous nephropathy with telitacicept","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14752","article-title":"A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report","volume":"26","author":"Chen","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298650","article-title":"Combination treatment with telitacicept, cyclophosphamide and glucocorticoids for severe Granulomatous polyangiitis: a case report and literature review","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i22.5309","article-title":"Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report","volume":"11","author":"Wang","year":"2023","journal-title":"World J Clin Cases."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1270011","article-title":"Case Report: Telitacicept in severe myasthenia gravis: a case study with multiple autoantibodies","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1279808","article-title":"Case Report: Telitacicept in treating a patient with NF155+ autoimmune nodopathy: a successful attempt to manage recurrent elevated sero-anti-NF155 antibodies","volume":"14","author":"Ren","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad088","article-title":"Good efficacy achieved by telitacicept, corticosteroids and immunosuppressants in the treatment of SLE combined with MOG-AD","volume":"7","author":"Tian","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000538033","article-title":"Telitacicept treatment refractory lupus nephritis: A case report","volume":"14","author":"Li","year":"2024","journal-title":"Case Rep Nephrol Dial."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/09612033231221911","article-title":"Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report","volume":"33","author":"Huang","year":"2024","journal-title":"Lupus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12036-y","article-title":"Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/09612033241233021","article-title":"Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review","volume":"33","author":"Fan","year":"2024","journal-title":"Lupus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/art.40930","article-title":"European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/10408363.2016.1200008","article-title":"Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond","volume":"53","author":"Xu","year":"2016","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2006.04.004","article-title":"BAFF, APRIL and human B cell disorders","volume":"18","author":"Tangye","year":"2006","journal-title":"Semin Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10875-005-4091-5","article-title":"Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Jonsson","year":"2005","journal-title":"J Clin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clim.2017.12.010","article-title":"Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP)","volume":"188","author":"Kamhieh-Milz","year":"2018","journal-title":"Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-353961","article-title":"TACI deficiency impairs sustained Blimp-1 expression in B cells decreasing long-lived plasma cells in the bone marrow","volume":"118","author":"Tsuji","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03161.x","article-title":"Splenic macrophages maintain the anti-platelet autoimmune response via uptake of opsonized platelets in patients with immune thrombocytopenic purpura","volume":"7","author":"Kuwana","year":"2009","journal-title":"J Thromb Haemost."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315608254","article-title":"Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus","volume":"25","author":"Salazar-Camarena","year":"2016","journal-title":"Lupus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mah\u00e9vas","year":"2015","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003860","article-title":"Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia","volume":"5","author":"Yu","year":"2021","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.03.014","article-title":"B-cell depletion in immune thrombocytopenia","author":"Godeau","year":"2013","journal-title":"Semin Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead171","article-title":"Early glucocorticoid withdrawal by combining rituximab with belimumab in two patients with lupus-associated thrombocytopenia","volume":"62","author":"Hanai","year":"2023","journal-title":"Rheumatol (Oxford)."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00303","article-title":"Belimumab and rituximab in systemic lupus erythematosus: A tale of two B cell-targeting agents","volume":"7","author":"Wise","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00433","article-title":"Association between changes in BLyS levels and the composition of B and T cell compartments in patients with refractory systemic lupus erythematosus treated with belimumab","volume":"10","author":"Regola","year":"2019","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.coi.2021.06.012","article-title":"Keeping up with the stress of antibody production: BAFF and APRIL maintain memory plasma cells","volume":"71","author":"Cornelis","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-024-02501-x","article-title":"Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study","volume":"28","author":"Huang","year":"2024","journal-title":"Clin Exp Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/rheumatology\/kead265","article-title":"Efficacy and safety of telitacicept in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"63","author":"Xu","year":"2024","journal-title":"Rheumatol (Oxford)."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cns.13904","article-title":"Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single-center, single-arm, open-label study","volume":"28","author":"Ding","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223529","article-title":"BLyS\/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept","volume":"82","author":"Cai","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27227859","article-title":"Avocado seeds-mediated alleviation of cyclosporine A-induced hepatotoxicity involves the inhibition of oxidative stress and proapoptotic endoplasmic reticulum stress","volume":"27","author":"El-Magd","year":"2022","journal-title":"Molecules"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.rdc.2017.09.003","article-title":"Drug-induced gastrointestinal and hepatic disease associated with biologics and nonbiologic disease-modifying antirheumatic drugs","volume":"44","author":"Wood","year":"2018","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1473190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T01:16:43Z","timestamp":1742347003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1473190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1473190"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1473190","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"1473190"}}